Parotid gland

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Tuesday, November 14, 2023
CNS, DSM-IV codes, DNA, Conditional sentence, Janssen Pharmaceuticals, Subthalamic nucleus, Patient, Research, ESGCT, FTD, Capsid, Quality control, Congress, I&I, Safety, Treatment, IND, Immunology, Inherited disorders of trafficking, ROFN, Evercore, Genome, STN, Central nervous system, Martin Lipton, Frontotemporal dementia, Xerostomia, Johnson & Johnson, MIA, GMP, Gene, BLA, Commercial, Insurance, Parotid gland, ALS, Parkinson's disease, Clinical trial, Obesity, QC, File, CGMP, RIX, Pharmaceutical industry, Vaccine, Cryptocurrency, Birth control, Sanofi, Janssen, Inflammation

Bota-vec for the Treatment of XLRP:

Key Points: 
  • Bota-vec for the Treatment of XLRP:
    Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
  • Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
  • License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Retrieved on: 
Thursday, December 8, 2022
DDS, Eye, Annual report, Head, Clinical trial, Failure, Nature, Parotid duct, Security (finance), Public opinion, Unilateralism, FDA, Safety, 8-K, Oral medicine, Stensen, Loss, Trial of the century, Gene expression, Central nervous system, Neurodegeneration, Xerostomia, Form 10-K, Patient, Parotid gland, Retina, COVID-19, RIX, Pharmaceutical industry

A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/ .

Key Points: 
  • A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/ .
  • MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
  • Unless otherwise stated or the context otherwise requires, the information herein is as of December 8, 2022.

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation

Retrieved on: 
Monday, November 29, 2021
Patient, Stensen, DDS, Xerostomia, Safety, RIX, Oral medicine, Technology, Head, Retina, Clinical trial, Parotid duct, Gene expression, Central nervous system, Investor, Department, Neurodegeneration, Eye, GLOBE, Riboswitch, RNA, Webcast, Parotid gland, NEW, NASDAQ, Degenerative disease, Pharmaceutical industry, Vaccine

MeiraGTx will also host a virtual R&D Day via webcast and conference call that will be held on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m.

Key Points: 
  • MeiraGTx will also host a virtual R&D Day via webcast and conference call that will be held on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m.
  • ET to focus on the Companys gene regulation platforms.
  • The event will provide a detailed overview of the Companys riboswitch gene regulation platform and an audience question and answer session.
  • MeiraGTx is pioneering a transformative platform technology that allows precise activation of gene expression with proprietary oral small molecule inducers.

FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea

Retrieved on: 
Monday, August 26, 2019
Organ systems, Drugs, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Spasmodic torticollis, Salivary gland, Parotid gland, Tooth decay, Submandibular gland

The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2

Key Points: 
  • The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2
    "We are committed to helping patients who struggle with confidence due to their sialorrhea.
  • MYOBLOC was first approved by the FDA in 2000 for the treatment of adults with cervical dystonia.
  • - injected into the salivary glands (parotid and submandibular glands) and used to treat chronic sialorrhea in adults.
  • The effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

Retrieved on: 
Thursday, August 9, 2018
Cancer, Medicine, Clinical medicine, Antineoplastic drugs, Salivary gland tumour, Pembrolizumab, Salivary gland, Targeted therapy, Cetuximab, Epidermal growth factor receptor, Chemotherapy, Parotid gland

Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.

Key Points: 
  • Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.
  • The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor).
  • Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda.
  • Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.